Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Total Liabilities (2017 - 2025)

Historic Total Liabilities for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $56.3 million.

  • Protagonist Therapeutics' Total Liabilities fell 2181.06% to $56.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.3 million, marking a year-over-year decrease of 2181.06%. This contributed to the annual value of $69.4 million for FY2024, which is 22636.08% up from last year.
  • Protagonist Therapeutics' Total Liabilities amounted to $56.3 million in Q3 2025, which was down 2181.06% from $50.0 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Total Liabilities ranged from a high of $73.3 million in Q2 2024 and a low of $21.3 million during Q4 2023
  • Over the past 5 years, Protagonist Therapeutics' median Total Liabilities value was $46.5 million (recorded in 2022), while the average stood at $46.2 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first tumbled by 4907.13% in 2023, then surged by 22636.08% in 2024.
  • Quarter analysis of 5 years shows Protagonist Therapeutics' Total Liabilities stood at $47.7 million in 2021, then plummeted by 32.21% to $32.3 million in 2022, then plummeted by 34.18% to $21.3 million in 2023, then skyrocketed by 226.36% to $69.4 million in 2024, then decreased by 18.98% to $56.3 million in 2025.
  • Its Total Liabilities stands at $56.3 million for Q3 2025, versus $50.0 million for Q2 2025 and $53.1 million for Q1 2025.